InventisBio Co., Limited (SHA:688382)
China flag China · Delayed Price · Currency is CNY
23.60
-0.12 (-0.51%)
At close: May 23, 2025, 2:57 PM CST

InventisBio Company Description

InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China and the United States.

The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; D-0502, which is in Phase I clinical trial for the breast cancer indications; and D-1553, which in Phase I clinical trial for NSCLS, colorectal cancer indications.

Its drug candidates for the metabolic therapeutic area is D-0120, a Phase I and II clinical trial product for hyperuricemia and gout indications.

The company has a collaboration agreement with Betta Pharmaceuticals. InventisBio Co., Limited was founded in 2013 and is headquartered in Pudong, China.

InventisBio Co., Limited
Country China
Founded 2013
Industry Biotechnology
Sector Healthcare
Employees 185
CEO Yaolin Wang

Contact Details

Address:
No.4, Libing Road
Pudong, 201203
China
Phone 86 21 5077 8527
Website inventisbio.com

Stock Details

Ticker Symbol 688382
Exchange Shanghai Stock Exchange
Fiscal Year January - December
Reporting Currency CNY
SIC Code 2836

Key Executives

Name Position
Dr. Yaolin Wang Chief Executive Officer and Chairman
Luwei Shi Chief Financial Officer, Chief Accountant and Director
Xing Dai Deputy GM and Director
Zhang Ling Deputy GM and Chief Medical Officer
Yueheng Jiang Deputy GM, Secretary and Director